CoughNCT02039999
An Investigation Into the Mechanism of Inhalation Cough Challenge
A study testing Nebulised citric acid in serial dilutions, Nebulised ATP solution in serial dilutions and Nebulised TRPA1 agonist solution in serial dilutions in people with Cough, run by Hull University Teaching Hospitals NHS Trust at 1 site in United Kingdom.
Trial summary
Despite its commonplace use in respiratory medicine the mechanism whereby inhalation challenge with a variety of mild acid aerosols produces a dose related and predictable cough is unknown. Read more about this study
- Who is it for?
- Ages 16 to 85 yearsHealthy volunteers can take part
- Conditions the study is for
- Cough
- What is being tested?
- Nebulised citric acid in serial dilutions, Nebulised ATP solution in serial dilutions and Nebulised TRPA1 agonist solution in serial dilutions
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- Feb 2015to Aug 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 to 85 years
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Patients will be required to demonstrate significant cough symptoms by a score greater than 20/70 on the Hull Airways Reflux Questionnaire.
- All patients must be current non-smokers.
- Patients must be on stable medication for at least one month.
- Patients must be able to attend the trials unit on at least 3 occasions.
- Patients must have normal lung function patients must be able to give informed consent
Who cannot join
- Subjects who are pregnant, or have pacemakers in situ are excluded from this study.
- Those with a serious comorbid conditions such as cancer, severe COPD, or heart failure will be excluded.
- Those who are non-English speakers and special groups (i.e. mentally ill, children under 16 years of age, and those suffering from dementia) will be excluded.
- No test will be performed on any subject during an acute worsening of asthma or upper airway infection. If the subject has had an upper airway infection in the last three weeks they will be offered another appointment.
- If the subject has taken any over the counter (OTC) cough mixture within the last twelve hours: If the subject is willing to come back another time for challenge testing, another appointment should be made.
- If the subject has had any food or drink products containing caffeine or menthol within the last hour. If the subject is unwilling to wait for 1 hour before starting the test, the subject should return another time. If the subject is unwilling to return another time, testing should proceed and the medication used recorded.
- If the participant is currently involved in research, or within 3 months of participation in any type of research, they will be excluded from this study.
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Hull Clinical Trials Unit, Respiratory academic department
Cottingham, East Yorkshire, HU16 5JQ
About this study
Despite its commonplace use in respiratory medicine the mechanism whereby inhalation challenge with a variety of mild acid aerosols produces a dose related and predictable cough is unknown. In this proposal the investigators wish to use established cough challenge methodology to explore the mechanism of action of agents provoking cough both in health and disease.
The hypotheses to be tested include:
- Intracellular changes in pH, rather than extracellular changes, are key in the activation of TRP receptors, the main sensor for provoking cough.
- ATP acting through P2X channels is the mechanism of increased nerve excitability underlying cough hypersensitivity.
Read the detailed description
The investigators have previously demonstrated that mild acids, such as citric, tartaric or phosphoric acid produce a highly reliable cough challenge and that the sensitivity of these are complex individual acids correlates within the population studied inferring a common mechanism of action.In contrast there is no correlation with the other common cough challenge methodology, capsaicin inferring that there are at least two different mechanisms for producing cough with aerosols in man.
Over the past 10 years it has been established that capsaicin works by a specific irritant receptor known as the TRPV1. A second receptor, TRPA1 has been recently discovered and we were the first group to demonstrate that inhalation of agonists of this receptor in the form of the extract of cinnamon (cinnamaldehyde) produces cough in man . TRPA1 is a very attractive candidate for the main cough receptor since it is activated by many common irritants, such as smoke, perfumes and other strong smells known to provoke coughing in patients.
The investigators have cloned the human TRP receptors and expressed them in cell lines. This in vitro work has allowed us to investigate the molecular action of the TRP receptors. Recently, the investigators and others have shown that weak acids can activate TRPA1, not as previously thought by stimulating the external surface of the cells but by altering the intracellular pH. This would explain why weak and not strong acids are better at producing cough, since weaker acids (technically those with a higher pKa) exist in solution in a form which is able to cross the cell membrane and render a change in the intracellular pH, which in turn activates TRPA1 from inside the cell.
In the first study the investigators wish to the simply alter the pH of the nebulised solution provoking cough by altering the balance of the salts in the solution, and then carry out standard cough challenge protocols.
In a second study the investigators wish to examine the effect of a number of known agonists of TRPA1 which are commonly used in the perfumes and foodstuffs in order to understand the rank order of potency of these compounds as tussive agents. This can then be compared to the rank order of potency of the same compounds in causing intracellular pH change in in vitro cell culture systems, in order to test the strength of the hypothesis over a variety of different agonists.
Finally, recent work has shown that blockade of a neuronal ion channel known as P2X3 can dramatically reduce cough. P2X3 responds to the substance adenosine triphosphate (ATP), which has previously been used as a cough challenge solution in man. If the hypothesis that the cough hypersensitivity seen in patients is due to activation of P2X3 is correct then patients will cough at much lower doses of ATP than normal volunteers. We wish to assess the value of ATP, and the related substance AMP and adenosine in a cough challenge protocol. Studying the cough produced by these naturally occurring compounds may allow us to distinguish patients with cough hypersensitivity from those with cough due to other causes, and also lead to a methodology important in future drug development
The greater understanding of the cough reflex which these studies would yield would have important clinical applications pointing the way to novel therapeutic avenues, as well as enhancing our fundamental understanding of the genesis of cough.
- Conditions
- Cough
- Being tested
- Nebulised citric acid in serial dilutions, Nebulised ATP solution in serial dilutions, Nebulised TRPA1 agonist solution in serial dilutions
- Keywords
- chronic, cough, challenge, ATP, hypersensitivity, TRPA1
- Medical subject headings
- Cough, Bronchiolitis Obliterans Syndrome, Hypersensitivity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nebulised citric acid in serial dilutionsOther
Citric acid will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
Nebulised ATP solution in serial dilutionsOther
ATP solution will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
Nebulised TRPA1 agonist solution in serial dilutionsOther
TRPA1 agonist will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
| Study group | Role | What they receive |
|---|---|---|
| Chronic cough | Experimental | Cough challenges to be administered include:
Nebulised citric acid in serial dilutions Nebulised ATP solution in serial dilutions Nebulised TRPA1 agonist solution in serial dilutions Receives: Other: Nebulised citric acid in serial dilutions; Other: Nebulised ATP solution in serial dilutions; Other: Nebulised TRPA1 agonist solution in serial dilutions |
| Normal volunteer | Active comparator | Cough challenges to be administered include:
Nebulised citric acid in serial dilutions Nebulised ATP solution in serial dilutions Nebulised TRPA1 agonist solution in serial dilutions Receives: Other: Nebulised citric acid in serial dilutions; Other: Nebulised ATP solution in serial dilutions; Other: Nebulised TRPA1 agonist solution in serial dilutions |
What is being measured
The primary outcome is the main question the study is designed to answer.
Difference in mean C5 (concentration of inhaled substance required to elicit 5 coughs) (ATP) and total cough (citric acid) between the chronic cough arm and the normal volunteer arm.
Following inhalation of challenge substance, subject will be monitored for 30 seconds and number of coughs recorded. Concentration of challenge substance will increase until subject coughs at least 5 times following challenge. This will be recorded as the C5 value for each subject. The mean C5 value will be compared between the chronic cough arm and the normal volunteer arm. This will be reported as whether or not there is a statistical difference between the mean C5 for the chronic cough group and the normal volunteer group.
Measured: Coughs will be measured in a 30 second period following the inhalation of each challenge substance.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jan 2014 (estimated)
- Study startFeb 2015
- Primary completionJul 2015
- Study completionAug 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for CoughStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hull University Teaching Hospitals NHS Trust
- Sponsor type
- Other government
- Responsible party
- Sponsor
- Investigators
- Alyn H Morice, MD, FRCP, Principal investigator, National Health Service, United Kingdom
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02039999
- Sponsor's protocol ID
- ACADMED240913
- Status last verified
- Jul 2019
- First submitted
- 16 Dec 2013
- Last updated
- 15 Jul 2019
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Fowles HE, Rowland T, Wright C, Morice A. Tussive challenge with ATP and AMP: does it reveal cough hypersensitivity? Eur Respir J. 2017 Feb 8;49(2):1601452. doi: 10.1183/13993003.01452-2016. Print 2017 Feb.
PubMed 28179439
Study at a glance
From the registry record, last updated by the sponsor on 15 Jul 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Investigation Into the Mechanism of Inhalation Cough Challenge
- ClinicalTrials.gov ID
- NCT02039999
- Acronym / sponsor ID
- ACADMED240913
- Conditions
- Cough
- Keywords
- chronic, cough, challenge, ATP, hypersensitivity, TRPA1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Hull University Teaching Hospitals NHS TrustOther government
- Study start
- Feb 2015
- Primary completion
- Jul 2015 (actual)
- Study completion
- Aug 2016 (actual)
- First posted
- 20 Jan 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Despite its commonplace use in respiratory medicine the mechanism whereby inhalation challenge with a variety of mild acid aerosols produces a dose related and predictable cough is unknown. In this proposal the investigators wish to use established cough challenge methodology to explore the mechanism of action of agents provoking cough both in health and disease.
The hypotheses to be tested include:
- Intracellular changes in pH, rather than extracellular changes, are key in the activation of TRP receptors, the main sensor for provoking cough.
- ATP acting through P2X channels is the mechanism of increased nerve excitability underlying cough hypersensitivity.
Detailed description
The investigators have previously demonstrated that mild acids, such as citric, tartaric or phosphoric acid produce a highly reliable cough challenge and that the sensitivity of these are complex individual acids correlates within the population studied inferring a common mechanism of action.In contrast there is no correlation with the other common cough challenge methodology, capsaicin inferring that there are at least two different mechanisms for producing cough with aerosols in man.
Over the past 10 years it has been established that capsaicin works by a specific irritant receptor known as the TRPV1. A second receptor, TRPA1 has been recently discovered and we were the first group to demonstrate that inhalation of agonists of this receptor in the form of the extract of cinnamon (cinnamaldehyde) produces cough in man . TRPA1 is a very attractive candidate for the main cough receptor since it is activated by many common irritants, such as smoke, perfumes and other strong smells known to provoke coughing in patients.
The investigators have cloned the human TRP receptors and expressed them in cell lines. This in vitro work has allowed us to investigate the molecular action of the TRP receptors. Recently, the investigators and others have shown that weak acids can activate TRPA1, not as previously thought by stimulating the external surface of the cells but by altering the intracellular pH. This would explain why weak and not strong acids are better at producing cough, since weaker acids (technically those with a higher pKa) exist in solution in a form which is able to cross the cell membrane and render a change in the intracellular pH, which in turn activates TRPA1 from inside the cell.
In the first study the investigators wish to the simply alter the pH of the nebulised solution provoking cough by altering the balance of the salts in the solution, and then carry out standard cough challenge protocols.
In a second study the investigators wish to examine the effect of a number of known agonists of TRPA1 which are commonly used in the perfumes and foodstuffs in order to understand the rank order of potency of these compounds as tussive agents. This can then be compared to the rank order of potency of the same compounds in causing intracellular pH change in in vitro cell culture systems, in order to test the strength of the hypothesis over a variety of different agonists.
Finally, recent work has shown that blockade of a neuronal ion channel known as P2X3 can dramatically reduce cough. P2X3 responds to the substance adenosine triphosphate (ATP), which has previously been used as a cough challenge solution in man. If the hypothesis that the cough hypersensitivity seen in patients is due to activation of P2X3 is correct then patients will cough at much lower doses of ATP than normal volunteers. We wish to assess the value of ATP, and the related substance AMP and adenosine in a cough challenge protocol. Studying the cough produced by these naturally occurring compounds may allow us to distinguish patients with cough hypersensitivity from those with cough due to other causes, and also lead to a methodology important in future drug development
The greater understanding of the cough reflex which these studies would yield would have important clinical applications pointing the way to novel therapeutic avenues, as well as enhancing our fundamental understanding of the genesis of cough.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Chronic cough | Experimental | Other: Nebulised citric acid in serial dilutions, Other: Nebulised ATP solution in serial dilutions, Other: Nebulised TRPA1 agonist solution in serial dilutionsCough challenges to be administered include: Nebulised citric acid in serial dilutions Nebulised ATP solution in serial dilutions Nebulised TRPA1 agonist solution in serial dilutions |
| Normal volunteer | Active comparator | Other: Nebulised citric acid in serial dilutions, Other: Nebulised ATP solution in serial dilutions, Other: Nebulised TRPA1 agonist solution in serial dilutionsCough challenges to be administered include: Nebulised citric acid in serial dilutions Nebulised ATP solution in serial dilutions Nebulised TRPA1 agonist solution in serial dilutions |
Who may qualify
- Ages
- 16 to 85 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (5 listed)
- Patients will be required to demonstrate significant cough symptoms by a score greater than 20/70 on the Hull Airways Reflux Questionnaire.
- All patients must be current non-smokers.
- Patients must be on stable medication for at least one month.
- Patients must be able to attend the trials unit on at least 3 occasions.
- Patients must have normal lung function patients must be able to give informed consent
Key exclusion criteria (7 listed)
- Subjects who are pregnant, or have pacemakers in situ are excluded from this study.
- Those with a serious comorbid conditions such as cancer, severe COPD, or heart failure will be excluded.
- Those who are non-English speakers and special groups (i.e. mentally ill, children under 16 years of age, and those suffering from dementia) will be excluded.
- No test will be performed on any subject during an acute worsening of asthma or upper airway infection. If the subject has had an upper airway infection in the last three weeks they will be offered another appointment.
- If the subject has taken any over the counter (OTC) cough mixture within the last twelve hours: If the subject is willing to come back another time for challenge testing, another appointment should be made.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nebulised citric acid in serial dilutionsCitric acid will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited. | Other | Chronic cough, Normal volunteer |
| Nebulised ATP solution in serial dilutionsATP solution will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited. | Other | Chronic cough, Normal volunteer |
| Nebulised TRPA1 agonist solution in serial dilutionsTRPA1 agonist will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited. | Other | Chronic cough, Normal volunteer |
Primary outcome
Difference in mean C5 (concentration of inhaled substance required to elicit 5 coughs) (ATP) and total cough (citric acid) between the chronic cough arm and the normal volunteer arm.
Time frame: Coughs will be measured in a 30 second period following the inhalation of each challenge substance.
Following inhalation of challenge substance, subject will be monitored for 30 seconds and number of coughs recorded. Concentration of challenge substance will increase until subject coughs at least 5 times following challenge. This will be recorded as the C5 value for each subject. The mean C5 value will be compared between the chronic cough arm and the normal volunteer arm. This will be reported as whether or not there is a statistical difference between the mean C5 for the chronic cough group and the normal volunteer group.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jul 2019.
- Background: PubMed 28179439Fowles HE, Rowland T, Wright C, Morice A. Tussive challenge with ATP and AMP: does it reveal cough hypersensitivity? Eur Respir J. 2017 Feb 8;49(2):1601452. doi: 10.1183/13993003.01452-2016. Print 2017 Feb.
- Publication LinkLink provided by the sponsor.
Related trials for Cough
RecruitingPhase 2
The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)
Refractory Chronic Cough
RecruitingObservational study
Physical Impairments in Premature Ventricular Complex
Premature Ventricular Complexes
RecruitingObservational study
Office-Based Superior Laryngeal Nerve Block for Treatment of Neurogenic Cough
Cough
Not yet recruiting
High-Flow Nasal Oxygen-Assisted Deep Extubation Versus Awake Extubation in Morbidly Obese Patients
Deep Tracheal Extubation
Recruiting
Feasibility of Cough Skill Training in Individuals With Head and Neck Cancer
Head and Neck Cancers
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alyn H Morice, MD, FRCP principal investigator
National Health Service, United Kingdom
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nebulised citric acid in serial dilutions, Nebulised ATP solution in serial dilutions and Nebulised TRPA1 agonist solution in serial dilutions in people with Cough, run by Hull University Teaching Hospitals NHS Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Difference in mean C5 (concentration of inhaled substance required to elicit 5 coughs) (ATP) and total cough (citric acid) between the chronic cough arm and the normal volunteer arm. (time frame: Coughs will be measured in a 30 second period following the inhalation of each challenge substance.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02039999, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jul 2019.